Business
Sionna Therapeutics Reports First Quarter 2026 Financial Results
Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on track for the summer of 2026 Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is also on track for topline data in the summer of 2026 Maintained strong cash position with approximately $289.9 million in cash
About this update from Sionna Therapeutics, Inc.
[{"type":"image","alt":"Sionna Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Sionna Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/9f8d8c0e203777999006c0b8c8d0c418"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/COfkmNe0HLR2vVwmA9j4RA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/9f8d8c0e203777999006c0b8c8d0c418","width":300,"height":300},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/COfkmNe0HLR2vVwmA9j4RA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/9f8d8c0e203777999006c0b8c8d0c418","width":300,"height":300}},"lazy":false},{"type":"text","content":"Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on track for the summer of 2026","length":224,"tagName":"p"},{"type":"text","content":"Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is also on track for topline data in the summer of 2026","length":201,"tagName":"p"},{"type":"text","content":"Maintained strong cash position with approximately $289.9 million in cash and cash equivalents, expected to fund operations into 2028","length":133,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) today reported financial results for the first quarter ended March 31, 2026, and provided a business update.","length":328,"tagName":"p"},{"type":"text","content":"“We entered 2026 with strong execution across our programs, highlighted by the recent completion of enrollment in our proof-of-concept Phase 2a trial of SION-719, an important milestone for Sionna,” said Mike Cloonan, President and Chief Executive Officer of Sionna. “With both of our clinical stage NBD1 stabilizer programs on track for topline readouts this summer, we remain focused on advancing these first-in-class product candidates that could expand therapeutic options for people with CF.”","l...